News
| 14 May 2011: | TPI files patents on interconnecting bioreactors using gravity flow |
| 26 April 2011: | TPI files patents on methods of monoclonal antibody manufacturing in flexible disposable bioreactors |
| 23 April 2011: | TPI files patents for the first separative bioreactor |
| 25 March 2011: | TPI begins construction of its new facility to manufacture 100-200 Kg of etanercept TPI begins construction of its new facility to manufacture 100-200 Kg of rituximab |
| 20 March 2011: | TPI files patents on a novel process of protein harvesting and purification that is projected to save over 50% cost of recombinant drug manufacturing |
| 10 March 2011: | TPI signs technology transfer agreement to manufacture Interferon Beta. |
| 2 March 2011: | Medill article (view video) |
| 1 March 2011: | TPI completes validation of its proprietary bioreactor line, MayaBio®, to manufacture bacterial proteins in 2-D plastic bags in a completely disposable system |
| 17 July 2010: | TPI begins development of applications of a novel technology to enhance the in vitro and in vivo stability of monoclonal antibodies. Applications include second generation rituxan, infliximab, trastuzumab, bevacizumab, adalimumab, cetuximab and etanercept. The technology involves strengthening the backbone of the antibody/protein and developing recombinant CHO-based cell lines to express these second generation biological drugs—clinical supplies to be ready in 2011. |
